ABSTRACT Background: Epidemiologic studies have suggested that a higher intake of flavonoids may be associated with lower risk of ischemic heart disease. However, the traditional estimation of flavonoid intake by using dietary assessment methods is affected by subjective measures. Objective: We examined whether the objective measurement of dietary flavonoids excreted in urine is associated with lower risk of acute coronary syndrome (ACS). Design: A case-control study was nested in the Danish Diet, Cancer and Health cohort study. Cases were identified in participants who had received a first-time ACS diagnosis in the Danish National Patient Registry after the time of enrollment into the Diet, Cancer and Health study. The excretion of 10 flavonoids, which represent 5 subclasses, was measured in spot urine samples by using liquid chromatography-mass spectrometry. Results: A total of 393 eligible cases with ACS were identified and matched to 393 noncases by using incidence density sampling. For kaempferol, most of the individual ORs were statistically significant and from 42% to 61% lower when the higher 4 quintiles were compared with the lowest quintile. The P-trend was not significant. For daidzein, individual ORs were 5-38% lower. None of the individual ORs were significant, but the P-trend was 0.041. For the remaining flavonoids, there were no significant relations between urinary excretion and risk of ACS. Conclusions: Except for kaempferol and daidzein, there were no significant associations between the urinary excretion of flavonoids and risk of ACS. A lack of relations may be a result of the use of shortterm exposure measures.
INTRODUCTION
Acute coronary syndrome (ACS) 4 is a major global cause of morbidity and mortality. Lifestyle plays a pivotal role in the prevention of ischemic heart disease (IHD) including ACS, and protective measures include regular exercise, no smoking, and a healthy diet. Flavonoids constitute a large class within the group of polyphenolic compounds and are ubiquitously distributed in the plant kingdom. Hence, a diet high in fruit, vegetables, and other plant-based products is also a diet high in flavonoids. Several prospective epidemiologic studies have reported lower risk of IHD in participants with a higher flavonoid intake (1) (2) (3) (4) (5) (6) (7) (8) , although the evidence is not conclusive (6, (9) (10) (11) (12) (13) . The potential cardiovascular protective effects of flavonoids have been attributed to their antiinflammatory properties (14) and indirect antioxidant effects (15) .
Dietary assessment methods, such as diet histories or foodfrequency questionnaires (FFQs) combined with information from flavonoid databases have been used in epidemiologic studies to estimate flavonoid intake. There are numerous challenges in the estimation of the intake and exposure to flavonoids. These challenges are a result of the huge variety and diversity of flavonoids in foods that are influenced by several factors such as growth conditions, postharvest processing, storage, and cooking (16) (17) (18) (19) , affecting exposure and bioavailability (20) . In addition, there are limited data regarding the flavonoid content of specific and processed foods and an inadequate understanding of the extent of the absorption and metabolic fate of individual flavonoids. Finally, the gut microflora and genotype present additional interindividual variations in the exposure to flavonoids.
An alternative to the estimation of flavonoid intake by using dietary assessment methods is to measure their excretion in urine. This technique provides an objective method for the measurement of flavonoid exposure that is not influenced by subjective errors associated with dietary assessment methods.
In this nested case-control study, we have measured urinary concentrations of 10 dietary flavonoids from 393 cases with ACS and 393 noncases to investigate the association between exposure to flavonoids and risk of ACS. The measured compounds represent the following 5 subclasses of flavonoids: flavanones, flavonols, flavones, isoflavones, and dihydrochalcones, all of which represent different groups of fruit, vegetables, and other plant-based products (21) .
SUBJECTS AND METHODS

Design and study population
The Danish Diet, Cancer and Health study is an ongoing cohort study in 57,053 participants recruited between 1993 and 1997. Initially, 160,725 individuals aged 50-64 y who were living in the Copenhagen and Aarhus areas were invited to participate. At the end of the recruitment period, 27,177 men and 29,876 women had accepted the invitation. At enrollment, participants filled in questionnaires on diet and lifestyle, and biological material was collected together with anthropometric data. Blood, urine, and fat tissue were sampled and stored at 21508C. The study population has been described in detail previously (22) .
A nested case-control study (23) was designed by using incident ACS as the outcome. Cases were identified in the 1031 ACS cases in the validation study (24) . The cases had received a first-time ACS diagnosis in the Danish National Patient Registry between the time of their enrollment into the Diet, Cancer and Health study and the end of 2001. Cases were also studied in the case-cohort studies (25) (26) (27) (28) . Recruitment was restricted to the participants who had delivered their urine samples in the afternoon or evening for optimal detection of flavonoids. Controls were selected (1:1) by incidence density sampling in those cohort members who were alive and free of ACS at the time of diagnosis of the case and were matched by sex, age, smoking (never, former, or current) and, as close as possible, the time of day for blood and urine collection (volume not recorded). The time of urine collection was not recorded but was assumed to be the same time of day as the blood collection.
The diagnosis of ACS included unstable angina pectoris and fatal and nonfatal myocardial infarction as the outcome. Information on the disease endpoint was obtained by linking participants (via the unique identification number assigned to all Danish citizens) with central Danish registries of hospital discharge diagnoses and causes of death (International Classification of Diseases eighth revision codes 410-410.99, 427.27 and International Classification of Diseases 10th revision codes I20.0, I21-I21.9, I46.0-I46.9). Cases were classified according to symptoms, signs, coronary biomarkers, electrocardiograms, and autopsy findings in accordance with the current recommendations of the American Heart Association and the European Society of Cardiology (24) . A detailed description of the assessment and validation of cases of ACS was published previously (24 
Dietary and lifestyle variables
Information on individual dietary intakes was obtained by using a 192-item FFQ that was completed by all participants (22, 29, 30) . Participants were asked to report their average intakes of different food and beverage items over the past 12 mo within 12 possible categories that ranged from never to $8 times/d.
In addition to the FFQ, all participants also completed a questionnaire about lifestyle factors, such as smoking habits, alcohol intake, physical activity, and education. Anthropometric and clinical measurements were also measured at baseline. The questionnaire has been described in detail elsewhere (22) . Information from the lifestyle questionnaire on known or suspected risk factors for IHD was used to adjust for potential confounders.
Determination of flavonoids in urine
Urine concentrations of 10 flavonoids (hesperetin, naringenin, quercetin, kaempferol, isorhamnetin, tamarixetin, genistein, daidzein, apigenin, and phloretin) were determined by using HPLC-mass spectrometry (MS). Urine samples (450 mL) were subjected to enzymatic hydrolysis and solid-phase extraction before HPLC-MS analysis as described in detail previously (31, 32) . After complete evaporation, the residues were dissolved in 200 mL 1% aqueous formic acid with 10% methanol (vol:vol) and analyzed by using HPLC-MS (32) . Samples for external calibration curves were prepared by spiking blank urine samples with working solutions that resulted in a concentration of 1, 2, 20, 40, 100, 200, or 500 ng/mL urine (triplicate injections for each concentration). Calibration samples were otherwise treated exactly as the urine samples. Flavonoid concentrations in urine samples were determined as single determinations on the basis of external calibration curves that were not included in each series of samples. Furthermore, internal and external standards were included in each series of samples [ie, external standards (blank urine spiked with a single amount of all 10 flavonoids) were included at the beginning, during, and at the end of each series of samples, and a final adjustment was performed on the basis of 2 internal standards (single amount) in each series of samples]. The means of all CVs (%) were ,14% except for phloretin (20%) and quercetin (28%). External standard samples were included with every analysis.
Urine samples were analyzed in a random order. Because of the rather large number of samples, urine samples were divided into 4 periods, each period of which had its own calibration curve for quantification of the 10 flavonoids.
Because of the lack of information on urine volume, urinary creatinine was determined in 50 mL urine [diluted 1:2 with MilliQ water (Millipore Corporation)] by using Jaffe's method on a Hitachi 912 analyzer (Roche Diagnostics GmbH) for subsequent correction of the urine concentration.
Statistical methods
The 10 flavonoids were summed into a category named sum flavonoids (the sum of all 10 flavonoids) and the following 3 subclasses according to their structural relation: flavonols (quercetin, kaempferol, isorhamnetin, and tamarixetin), flavanones (hesperetin and naringenin) and isoflavones (genistein and daidzein). In addition, individual flavonoids hesperetin, naringenin, quercetin, kaempferol, isorhamnetin, tamarixetin, genistein, daidzein, apigenin, and phloretin were analyzed separately.
The association between the concentration of each type of flavonoid and the OR of ACS was assessed by using conditional logistic regression. The following known risk factors were included in the adjusted analyses: BMI (in kg/m 2 ), waist circumference, smoking (g tobacco/d), hypertension (self-reported supplied with information about medicine), self-reported history of diabetes (yes, no, or do not know), alcohol (g/d), hypercholesterolemia (self-reported supplied with information about medicine), physical activity (in 3 categories of #0.5, 0.5-3.5, and .3.5-30 h/wk) and level of school education (#7, 8-10, or .10 y). Each of the variables alcohol and BMI was modeled as a restricted cubic spline with 3 knots. Specifically for the flavonoid kaempferol, analyses were also performed without adjustment for alcohol because wine is one of the main sources of kaempferol. In addition, the adjusted analysis included adjustment for the period of analysis of urine samples (a categorical variable with 4 levels caused by changes in laboratory equipment).
We categorized flavonoid concentrations into quintiles on the basis of the distribution in cases and estimated ORs of ACS by using the lowest quintile as reference. Subsequently, we performed trend analyses by using conditional logistic regression on the quintile number to evaluate the overall trend of ORs over quintiles. A level of significance of 0.05 was used. Analyses were performed with Stata Statistical Software 11.2 (Stata Corp). Associations between flavonoids and soy products, tea, wine, and vegetables were reported by using Pearson's r.
RESULTS
Baseline statistics
A total of 1119 validated incident cases with ACS were identified at follow-up (24) . After restriction to participants recruited in the afternoon (between 1300 and 1800), a total of 500 cases were selected at random together with 500 incidence-density-matched controls. Subsequently, a total of 107 pairs were excluded because of missing urine samples (63 pairs), missing data from the lifestyle questionnaire (25 pairs), or laboratory failure (19 pairs) . This exclusion left a total of 393 pairs for the analysis.
Baseline characteristics of cases and noncases are shown in Table 1 . There was a higher prevalence of hypertension and hypercholesterolemia in cases than noncases, and cases had lower education than that of noncases. Cases were alcohol abstainers 2-3 times as often as noncases, and noncase men more-often (29.6% compared with 20.1%) consumed more than the official Danish recommendations of #21 U/wk. Noncases had significant higher vegetable, soy, wine, and tea intakes than did cases. Because of a few noncases with extraordinary high wine intakes, the 5th, 50th, and 95th percentiles for wine intake in noncases and cases were identical, although significantly different.
Risk of ACS and urinary flavonoid excretion
Unadjusted and adjusted ORs (95% CIs) for quintiles of urinary excretion of the sum of flavonoids, subclasses of flavonols, flavanones, isoflavones, and the individual flavonoids quercetin, kaempferol, isorhamnetin, tamarixetin, hesperetin, naringenin, genistein, daidzein, apigenin, and phloretin are shown in Table 2 . For the sum of flavonoids, there was no significant association between excretion and ACS risk with no sign of a dose-response relation (P-trend = 0.322). For the sum of flavonols, the association between excretion and ACS risk was not significant with no sign of a doseresponse relation (P-trend = 0.462). For individual flavonols, associations were mainly negative and with no sign of dose-response relations. For kaempferol not adjusted for alcohol, associations were both consistent and significant (ORs ,0.54 for urinary kaempferol excretions above the first quintile; P-trend = 0.115).
For the sum of flavanones and for all of individual flavanones, there were no significant dose-response relations between urinary excretion and risk of ACS. For the sum of isoflavones and for daidzein alone, significant negative dose-response relations were observed (P-trend = 0.034 and 0.041, respectively). No significant dose-response relation were observed for the flavan apigenin (P-trend = 0.734) and the dihydrochalcone phloretin (P-trend = 0.459). In all analyses, adjustment for potential confounders had a minor impact on study results.
Correlations between FFQ and urinary flavonoid excretion
Correlations between urinary kaempferol excretion and intakes of tea, wine, and vegetables were 0.34 (P , 0.0001), 0.17 (P , 0.0001), and 0.08 (P = 0.020), respectively. There were no correlations between the intake of soy products and the subclass of isoflavones or daidzein (r = 20.01, P = 0.893 and r = 20.01, P = 0.769, respectively).
DISCUSSION
The association between the urinary excretion of 10 dietary flavonoids and risk of ACS was explored in a nested case-control study within the Danish Diet, Cancer and Health study. Except for daidzein, there were no significant dose-response relations between the urinary excretion of flavonoids and ACS risk. Kaempferol excretion above the first quintile was significantly associated with consistent 46-62% lower risk of ACS. Lower risk associated with urinary kaempferol excretion was probably partly attributable to the intake of tea.
The study has several strengths such as the prospective design, detailed information on a wide range of potentially confounding factors, and the validated disease outcome (24) . The main advantage of assessing flavonoid exposure by measuring the amount excreted in urine, compared with estimating flavonoid intake on the basis of dietary assessment methods and flavonoid databases, is the elimination of influence by subjective variables such as memory and misreporting of dietary intake.
Most epidemiologic studies on flavonoid intake and risk of IHD have reported on inverse associations between flavonoid intake assessed by using an FFQ (either as a sum of flavonoids, subclasses, or individual flavonoids) and risk of IHD (1, 3, 5-8, 11, 13) . The lack of dose-response relations between urinary excretion of most of the flavonoids and risk of ACS in the current study have also been observed in epidemiologic studies that investigated the association between flavonoid intake and IHD or cardiovascular disease (5, 11, 33) . Several different explanations have been suggested for explaining this pattern as follows: it may indicate that no or a very low intake of flavonoids increases risk of IHD, that relatively small amounts of flavonoid intake may be beneficial (33) , or that a low intake is a surrogate measure for lifestyle risk factors related to risk of IHD (5) . A higher intake of flavonoids may also be an indicator of an overall healthier lifestyle that, besides including measurable behavioral elements such as being a nonsmoker, physically active, and having a moderate alcohol intake, also includes a wide range of more-subtle behavioral and psychosocial elements (34) .
Flavonols are the most widespread flavonoids in foods, and the most prominent flavonols in food are quercetin and kaempferol (14) . Some of the major dietary sources of kaempferol are tea, red wine, and vegetables such as broccoli (14, 21, 35, 36 ). In the current study, noncases had significantly higher dietary intakes of vegetables, wine, and tea assessed by using the FFQ than did cases. Epidemiologic data have suggested an association between a higher kaempferol intake and lower risk of IHD. This association is supported by the antiinflammatory properties of kaempferol in vitro and in vivo (37) . 4 n = 314 noncases; n = 314 cases. 5 n = 79 noncases; n = 79 cases. 3 Adjusted for period of analysis, BMI, waist circumference, smoking, hypertension, diabetes, alcohol, hypercholesterolemia, physical activity, and level of school education. The variables alcohol and BMI were modeled as restricted cubic splines with 3 knots. 4 Quercetin, kaempferol, isorhamnetin, tamarixitin, hesperetin, naringenin, genistein, daidzein, apigenin, and phloretin. 5 Quercetin, kaempferol, isorhamnetin, and tamarixitin. 6 Not adjusted for alcohol intake. 7 Hesperetin and naringenin. 8 Genistein and daidzein.
In the current study, we showed a significant dose-response relation between higher urinary concentrations of the isoflavone daidzein and lower risk of ACS. Another study measured the urinary excretion of isoflavones in spot urine samples (untimed) in a cohort of British women aged 45-75 y (38) . According to their data, the excretion of isoflavones in the current study was rather low, which perhaps reflected the male majority in the current study or that isoflavone-containing food was mainly consumed in the evening and, thus, not detected in the afternoon spot urine sample. A nested case-control study that measured the urinary excretion of isoflavonoids from cases with IHD and matched controls showed an inverse association between equol excretion and risk of IHD in women (39) . Equol was not measured in the current study but is a metabolite of daidzein. According to the FFQ in the current study, noncases had a higher intake of soy products than did cases. However, there were no correlations between daidzein or the subclass of isoflavones and the intake of soy products assessed by using the FFQ. This result could be attributable to the afternoon spot urine sample but was more likely a reflection of the inability of the FFQ to correctly estimate the consumption of soy products. Epidemiologic studies have suggested that differences in the amount of soy products in the diet may explain the lower incidence of IHD in Japan than in Western countries (40) . Several mechanisms of atheroprotective action have been proposed for isoflavones, but overall, their effectiveness in reducing risk of IHD is not clear (14, 40, 41) .
This study had several potential limitations. Although the method for measuring flavonoids excreted in urine is objective and, thus, not hampered by recall and estimation errors, the excretion of flavonoids in urine is influenced by several factors such as individual differences in absorption, metabolism, and distribution. Urine samples analyzed in the current study were afternoon spot urine samples. Afternoon spot urine samples represent a feasible alternative to overnight or 24-h urine samples. Overnight or 24-h urine samples are superior in relation to flavonoid excretion (42) but not realistic to obtain in a study with the magnitude of the Danish Diet, Cancer and Health cohort study. In general, flavonoids have elimination half-lives between 2 and 9 h and only a few exceed 24 h (43). Thus, urinary concentrations of flavonoids in a spot urine sample are a snapshot of exposure and highly affected by the structure of the flavonoid and when the flavonoid-containing food or drink has been consumed. Flavonoids are generally conjugated to various glycosides, and the nature of these glycosides is a major determinant for bioavailability and the elimination rate (31, 44, 45) . The consumption of a food or beverage that contains flavonoids with short to medium elimination half-lives (2-6 h) with breakfast would lead to detection of lower concentrations of flavonoids in an afternoon spot urine sample than if the food or beverage was consumed with lunch. In addition, if the majority of the daily consumption of flavonoid-rich food was consumed at dinner, it would not be detected in an afternoon spot urine sample. Thus, the time of consumption is the determining factor for placement into quintiles of flavonoid excretion. The short-term nature of flavonoid exposure may explain the lack of dose-response relations between risk of ACS and urinary flavonoid excretion observed in the current study. The strong negative association between urinary excretion of kaempferol, which was partly ascribed to tea consumption, and risk of ACS may have reflected that this drink was consumed regularly throughout the day and not confined to specific meals. There was a higher prevalence of hypertension and hypercholesterolemia in cases than noncases in the current study. Thus, the RR of developing IHD in cases compared with noncases might have been too high to observe any protective effect of the flavonoids on the basis of these risk factors alone. We acknowledge that CVs for flavonoid standards used in the urinary analysis were rather high for a few of the flavonoids (quercetin and phloretin) and might have reduced a negative association between urinary excretion of these flavonoids and risk of ACS.
Despite the limitations and possible misclassification within the current study, we observed strong negative associations between the urinary excretion of kaempferol and risk of ACS and a significant dose-response relation between higher urinary concentrations of daidzein and lower risk of ACS. Associations between individual compounds and disease risk in epidemiologic studies should always be considered with caution because of the lack of evidence for causality. However, results from the current study encourage the investigation of associations between the excretion of flavonoids and risk of ACS in larger populations.
In conclusion, except for kaempferol and daidzein, there are no significant negative associations between the urinary excretion of total or individual flavonoids and risk of ACS. The short-term nature of flavonoid exposure may explain the lack of dose-response relations.
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